Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT.

TO THE EDITOR: A recent ahead-of-print publication by Castello et al. ([1][1]) provides fascinating insights on the potential prognostic role of 18F-FDG PET/CT in patients with non–small cell lung cancer treated with immune checkpoint inhibitors (ICIs). The authors unraveled the prognostic value